Serum alpha klotho levels in Parkinson's Disease

Area of Science:

• Neuroscience
• Gerontology
• Biochemistry

Background:

• Parkinson's Disease (PD) is a debilitating neurodegenerative disorder with significant morbidity.
• Alpha-Klotho (α-Klotho), an anti-aging protein, exhibits neuroprotective properties and is of growing research interest.
• Understanding biomarkers for PD is crucial for early diagnosis and management.

Purpose of the Study:

• To investigate and compare serum α-Klotho levels in individuals with Parkinson's Disease (PD) versus healthy controls.
• To explore the association between α-Klotho levels and cognitive function in PD patients.

Main Methods:

• A cross-sectional case-control study involving 157 PD patients and 157 controls.
• PD diagnosis was confirmed using UK Parkinson Disease Society Brain Bank criteria.
• Serum α-Klotho levels were quantified using a commercial enzyme-linked immunosorbent assay (ELISA).

Main Results:

• PD patients exhibited significantly lower serum α-Klotho levels (0.85 nmol/L) compared to controls (1.47 nmol/L, p < 0.001).
• Lower α-Klotho levels were also observed in PD patients with dementia compared to those without.
• Logistic regression indicated α-Klotho as a significant predictor of PD (OR: 0.04, p < 0.001), with 90% sensitivity and 65% specificity.

Conclusions:

• Serum α-Klotho may serve as a potential diagnostic biomarker for Parkinson's Disease.
• Further research is warranted to validate these findings and explore the therapeutic potential of α-Klotho in PD.